Corient Private Wealth
HUMA icon

Corient Private Wealth’s Humacyte HUMA Stock Holding History

Corient Private Wealth’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$54.4K – 2426
2024
Q3 		$54.4K Buy
+10,000
New +$65.9K ﹤0.01% 2386

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corient Private Wealth's HUMA Position: Q4 2024 in Review

Corient Private Wealth sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 10,000 shares — an estimated $54.4K sold.

Corient Private Wealth first reported a position in HUMA in Q3 2024 and held it in 1 quarter. The position peaked at $54.4K in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • Corient Private Wealth reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • Corient Private Wealth sold 10,000 Humacyte shares in Q4 2024, an estimated $54.4K.
  • Corient Private Wealth first reported a position in Humacyte in Q3 2024 and held it in 1 quarter.
  • Corient Private Wealth's Humacyte position peaked at $54.4K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on Corient Private Wealth's 13F filing for Q4 2024, filed 10 Feb 2025.